Secretome Therapeutics Presents Scientific Poster on the Essential Role . . . Secretome Therapeutics’ scientific poster clarifies the critical role of the complete secretome in optimizing the therapeutic potential of regenerative cell therapy The secretome, comprised of bioactive molecules secreted by cells, has emerged as a key component in regenerative medicine
Archives | Secretome Therapeutics: Pioneering nCPC-Based Cardiovascular . . . DALLAS– (BUSINESS WIRE)–Secretome Therapeutics, a clinical-stage biotechnology company pioneering therapies derived from neonatal cardiac progenitor cells (nCPCs), today announced the appointment of Marshelle Smith Warren, MD, as Chief Medical Officer
Pipeline x | Secretome Therapeutics: Pioneering nCPC-Based . . . Cells grown in different conditions produce different secretomes, enabling Secretome Therapeutics to produce a pipeline of novel, patented secretomes that have the potential to address the many diseases that are driven by pathological inflammation, fibrosis, and apoptosis
Muthukumar Gunasekaran, PhD | Secretome Therapeutics: Pioneering nCPC . . . Dr Muthukumar Gunasekaran focuses on applying nCPC-derived therapies to neurodegenerative diseases, including ALS and Friedreich’s Ataxia He has 30+ publications in translational research and earned his PhD in Clinical Proteomics from the University of Verona